Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Extension Study for the Port Delivery System With Ranibizumab (Portal)
- Conditions
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03683251
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 363
- Registration Number
- NCT03684044
- Locations
- 🇯🇵
Naha City Hospital, Naha, Japan
🇯🇵Social Corporation Keigakukai Minamiosaka Hosupital, Osaka, Japan
🇯🇵National Hospital Organaization Shibukawa Medical Center, Shibukawa, Japan
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT03677154
- Locations
- 🇺🇸
Fort Wayne Medical Institute, Fort Wayne, Indiana, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT03677934
- Locations
- 🇺🇸
Retina Specialists, Towson, Maryland, United States
🇺🇸N CA Retina Vitreous Assoc, Mountain View, California, United States
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT03677141
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of California; Moores Cancer Center, La Jolla, California, United States
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT03674112
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Oncology - Memorial City, Houston, Texas, United States
🇨🇺Hospital Hermanos Ameijeiras, La Habana, Cuba
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 422
- Registration Number
- NCT03671018
- Locations
- 🇺🇸
University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT03669640
- Locations
- 🇺🇸
California Neuropsychopharmacology Clinical Research Institute, LLC, San Diego, California, United States
🇺🇸Synergy San Diego, Lemon Grove, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
- Conditions
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT03664804
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston; McGovern Medical School, Houston, Texas, United States
🇩🇪Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT03653364
- Locations
- 🇵🇱
IN VIVO Sp. z o.o., Bydgoszcz, Poland
🇺🇸Usf Health, Tampa, Florida, United States
🇺🇸Oak Cliff Research Company, LLC, Dallas, Texas, United States